Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial May 16, 2024
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards April 19, 2024
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion March 18, 2024
